Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

TGTX

+ Watchlist+ Portfolio

TG Therapeutics, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$62.71
52-Week Range
$26.76 – $68.03
Market Cap
$9.99B
P/E (TTM)
98.69
EPS (TTM)
0.67
Dividend Yield
0.00%
Advanced Metrics
Price/Book
16.19
PEG Ratio
1.61
Return on Equity
17.99%
Return on Assets
9.21%
Gross Margin
82.74%
Operating Margin
21.48%
Profit Margin
11.81%
Current Ratio
4.50
Debt/Equity
1.32
Total Debt
$754.37M
Free Cash Flow
$85.52M
Revenue Growth
60.70%
Earnings Growth
-85.60%
Enterprise Value
$9.51B

Market Snapshot

About

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, including chronic lymphocytic leukemia (CLL) and multiple sclerosis. The company markets BRIUMVI for relapsing forms of multiple sclerosis and continues advancing its pipeline of targeted immunotherapies.